<DOC>
	<DOCNO>NCT00379340</DOCNO>
	<brief_summary>This phase III trial study well combination chemotherapy without radiation therapy work treat young patient newly diagnose stage III stage IV Favorable Histology Wilms ' tumor . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving one drug ( combination chemotherapy ) without radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Radiation Therapy Treating Young Patients With Newly Diagnosed Stage III Stage IV Wilms ' Tumor</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine 4-year event-free survival ( EFS ) patient stage IV favorable histology ( FH ) Wilms ' tumor pulmonary metastasis complete resolution pulmonary lesion without whole lung irradiation treat DD4A chemotherapy comprise vincristine , dactinomycin , doxorubicin hydrochloride . II . Determine 4-year EFS patient resolution pulmonary metastasis week 6 treated addition cyclophosphamide etoposide modified-regimen DD4A ( regimen M ) . III . Determine 4-year EFS patient stage III IV FH Wilms ' tumor loss heterozygosity chromosomes 1p 16q treated regimen M. SECONDARY OBJECTIVES : I. Correlate burden pulmonary metastatic disease outcome patient stage IV FH Wilms ' tumor . OUTLINE : This multicenter study . REGIMEN DD4A ( week 1-6 ) : Patients receive dactinomycin IV 1-5 minute week 1 ; vincristine IV week 1-6 ; doxorubicin hydrochloride IV 15 minute week 4 absence disease progression unacceptable toxicity . Patients pulmonary extra-pulmonary metastasis diagnosis undergo radiotherapy daily begin week 1 continue 5-14 day . After completion DD4A chemotherapy ( week 6 ) , patient undergo evaluation . Patients stage IV disease pulmonary metastasis loss heterozygosity ( LOH ) rapid complete responder ( RCR ) ( i.e. , pulmonary metastasis disappear ) proceed regimen DD4A ( week 7-25 ) . All patient ( i.e. , patient stage III IV disease LOH 1p 16q ; stage IV disease pulmonary metastasis slow incomplete responder [ SIR ] [ i.e. , pulmonary metastasis disappear ] ; stage IV disease nonpulmonary metastasis nonpulmonary metastasis combination pulmonary metastasis proceed regimen M ( week 7-31 ) . Patients initially unresectable incompletely resect tumor reevaluate week 6 , resectable , undergo surgery proceed either regimen DD4A regimen M describe . REGIMEN DD4A ( week 7-25 ) : Patients receive dactinomycin IV 1-5 minute week 7 , 13 , 19 , 25 ; vincristine IV week 7-10 , 13 , 16 , 19 , 22 , 25 ; doxorubicin hydrochloride IV 15 minute week 10 , 16 , 22 absence disease progression unacceptable toxicity . REGIMEN M ( week 7-31 ) : Patients receive cyclophosphamide IV 1 hour etoposide IV 1 hour day 1-5 week 7 , 10 , 19 , 25 ; vincristine IV week 8 , 9 , 11 , 12 , 13 , 16 , 22 , 28 , 31 ; dactinomycin IV doxorubicin hydrochloride IV 15 minute week 13 , 16 , 22 , 28 , 31 absence disease progression unacceptable toxicity . Patients pulmonary metastasis SIR also undergo whole lung radiotherapy daily begin week 7 continue 5-14 day . NOTE : Patients begin study treatment undergo resection pulmonary metastasis eligible study . It recommend patient treat per current gold standard therapy chemotherapy accord regimen DD4A ( week 1-25 ) whole lung radiotherapy 5-14 day begin week 1 . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Newly diagnose Wilms ' tumor meeting 1 follow criterion : Stage IV disease favorable histology without loss heterozygosity ( LOH ) 1p 16q Stage III disease favorable histology LOH 1p 16q transfer clinical trial COGAREN0532 Patients must begin therapy within 14 day surgery biopsy , unless medically contraindicate No bilateral Wilms ' tumor ( stage IV ) Patients refer COGAREN0534 Previously enrol clinical trial COGAREN03B2 Karnofsky performance status ( PS ) 50100 % ( patient &gt; 16 year age ) OR Lansky PS 50100 % ( patient ≤ 16 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior tumordirected chemotherapy radiotherapy unless transfer clinical trial COGAREN0532 OR treatment emergent issue , medically indicate No concurrent aprepitant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>